Pfizer’s AstraZeneca deal could save it billions in U.S. tax

Pfizer Inc.’s attempted takeover of British pharmaceutical rival, AstraZeneca, if successful, could yield a massive loss to the U.S. Treasury as its offshore profits could permanently escape taxation. See, Jessie Drucker and Zachary R. Mider, Bloomberg; Richard Murphy, Tax Research U.K.; Liz Hoffman, Wall Street Journal; Jia Lynn Wang. Washington Post; Matthew Herper, Forbes